Randomized comparison of piperacillin-tazobactam plus amikacin versus cefoperazone-sulbactam plus amikacin for management of febrile neutropenia in children with lymphoma and solid tumors

Simple item page
dc.contributor.buuauthorDemirkaya, Metin
dc.contributor.buuauthorÇelebi, Solmaz
dc.contributor.buuauthorSevinir, Betül Berrin
dc.contributor.buuauthorHacımustafaoğlu, Mustafa Kemal
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Pediatrik Onkoloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Veterinerlik Fakültesi/Enfeksiyon Hastalıkları Anabilim Dalı.tr_TR
dc.contributor.researcheridEUG-4353-2022
dc.contributor.researcheridJHN-1091-2023
dc.contributor.researcheridAAH-1570-2021
dc.contributor.researcheridCTG-5805-2022
dc.contributor.scopusid24331130000tr_TR
dc.contributor.scopusid7006095295tr_TR
dc.contributor.scopusid6603199915tr_TR
dc.contributor.scopusid6602154166tr_TR
dc.date.accessioned2024-04-02T07:40:22Z
dc.date.available2024-04-02T07:40:22Z
dc.date.issued2013-03
dc.description.abstractThe objective of this study was to compare the effectiveness of piperacillin-tazobactam(PIP/TAZO) plus amikacin (AMK) (PIP/TAZO+AMK) versus cefoperazone-sulbactam (CS) plus AMK (CS+AMK) for the treatment of febrile neutropenia (FN) in children with cancer. The study was designed prospectively and randomized in 0- to 18-year-old children with lymphoma or solid tumor who were hospitalized with FN diagnosis. Consecutively randomized patients received either PIP/TAZO 360 mg/kg/day in 4 doses plus AMK 15 mg/kg/day in 3 doses or CS 100 mg/kg/day in 3 doses plus AMK 15 mg/kg/day in 3 doses intravenously. Treatment modification was defined as any change in the initial empirical antibiotic therapy. A total of 116 FN episodes were managed in 46 patients (26 boys and 20 girls) with a median age of 6.5 years (range .8-17.0) during the study period. Success rates without modification of therapy were 47.5% and 52.6% in PIP/TAZO+AMK group and CS+AMK group, respectively (P>.05). No statistical difference was found between treatment groups in terms of durations of neutropenia, fever, and hospitalization. The overall success rate in all groups was 97.4%. No major side effect was observed in either group during the course of the study. Our study is the first to compare the effectiveness of PIP/TAZO+AMK and CS+AMK therapies. Both combinations were effective and safe as empirical therapy for febrile neutropenic patients.en_US
dc.identifier.citationDemirkaya, M. (2013). “Randomized comparison of piperacillin-tazobactam plus amikacin versus cefoperazone-sulbactam plus amikacin for management of febrile neutropenia in children with lymphoma and solid tumors”. Pediatric Hematology and Oncology, 30(2), 141-148.en_US
dc.identifier.endpage148tr_TR
dc.identifier.issn0888-0018
dc.identifier.issue2tr_TR
dc.identifier.pubmed23301757tr_TR
dc.identifier.scopus2-s2.0-84873900578tr_TR
dc.identifier.startpage141tr_TR
dc.identifier.urihttps://doi.org/10.3109/08880018.2012.756565
dc.identifier.urihttps://www.tandfonline.com/doi/full/10.3109/08880018.2012.756565
dc.identifier.urihttps://hdl.handle.net/11452/40904
dc.identifier.volume30tr_TR
dc.identifier.wos000316567400009
dc.indexed.pubmedPubMeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherTaylor and Francisen_US
dc.relation.journalPediatric Hematology and Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectOncologyen_US
dc.subjectHematologyen_US
dc.subjectPediatricsen_US
dc.subjectAmikacinen_US
dc.subjectCefoperazone-sulbactamen_US
dc.subjectChildhood canceren_US
dc.subjectFebrile neutropeniaen_US
dc.subjectPiperacillin-tazobactamen_US
dc.subjectPediatric cancer-paitientsen_US
dc.subjectEmpirical-treatmenten_US
dc.subjectMonotherapyen_US
dc.subjectCefepimeen_US
dc.subjectTherapyen_US
dc.subjectFeveren_US
dc.subjectImipenemen_US
dc.subjectMetaanalysisen_US
dc.subjectNetilmicinen_US
dc.subjectInfectionen_US
dc.subject.emtreeAmikacinen_US
dc.subject.emtreePiperacillinen_US
dc.subject.emtreeSulperazonen_US
dc.subject.emtreeAdolescenten_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeChilden_US
dc.subject.emtreeChild hospitalizationen_US
dc.subject.emtreeClinical articleen_US
dc.subject.emtreeComparative effectivenessen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeDisease durationen_US
dc.subject.emtreeDrug efficacyen_US
dc.subject.emtreeFebrile neutropeniaen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeInfanten_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeNewbornen_US
dc.subject.emtreePreschool childen_US
dc.subject.emtreeProspective studyen_US
dc.subject.emtreeRandomized controlled trialen_US
dc.subject.emtreeSchool childen_US
dc.subject.emtreeTreatment outcome;en_US
dc.subject.emtreeUnspecified side effecten_US
dc.subject.meshAdolescenten_US
dc.subject.meshAmikacinen_US
dc.subject.meshAnti-bacterial agentsen_US
dc.subject.meshCefoperazoneen_US
dc.subject.meshChilden_US
dc.subject.meshChild, preschoolen_US
dc.subject.meshDrug therapy, combinationen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshInfanten_US
dc.subject.meshLymphoma, non-hodgkinen_US
dc.subject.meshMaleen_US
dc.subject.meshNeutropeniaen_US
dc.subject.meshPenicillanic aciden_US
dc.subject.meshPiperacillinen_US
dc.subject.meshProspective studiesen_US
dc.subject.meshSulbactamen_US
dc.subject.scopusCancer; Coagulase Negative Staphylococci; Piperacillin Plus Tazobactamen_US
dc.subject.wosOncologyen_US
dc.subject.wosHematologyen_US
dc.subject.wosPediatricsen_US
dc.titleRandomized comparison of piperacillin-tazobactam plus amikacin versus cefoperazone-sulbactam plus amikacin for management of febrile neutropenia in children with lymphoma and solid tumorsen_US
dc.typeArticleen_US

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
PubMed
Scopus